Can a new pill outsmart Treatment-Resistant blood cancer?
NCT ID NCT07753369
First seen Aug 07, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This phase III trial is testing whether an experimental drug called TQB3909 can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) whose disease has returned or stopped responding to prior treatments. Participants will be randomly assigned to receive either TQB3909 tablets or one of several standard treatment options chosen by their doctor. The main goal is to see if TQB3909 can delay disease progression better than the standard choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TQB3909, an experimental BCL-2 inhibitor taken as a tablet
- What this could lead to
- If successful, TQB3909 could offer a new, more effective treatment option for people with CLL/SLL whose disease has returned or stopped responding to current therapies.
- What could go wrong
- This is an early-stage comparison, and the drug may not prove better than existing options. As with any cancer therapy, there are risks of side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Province
Zhengzhou, Henan, China
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New cell therapy takes aim at Hard-to-Treat blood cancers
- Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
- New shot for tough blood cancers enters first human tests
- New drug combo shows promise for Tough-to-Treat leukemia
- New 'Four-in-One' antibody takes on Hard-to-Treat blood cancers
- New antibody combo shows promise for Tough-to-Treat blood cancers